Company news

Amgen Inc. news in 2025

Amgen Inc.'s news releases, calls and decks from 2025, newest first.

View company

Amgen and Kyowa Kirin provide top-line results from rocatinlimab phase 3 IGNITE study in adults with moderate to severe atopic dermatitis

March 7, 2025

Amgen announces 2025 second quarter dividend

March 3, 2025

Positive results from TEZSPIRE® (tezepelumab-ekko) phase 3 waypoint trial highlight rapid, sustained effect in chronic rhinosinusitis with nasal polyps

February 28, 2025

Amgen to present at the 45th annual td cowen health care conference

February 27, 2025

Amgen to present at citi's 2025 virtual oncology leadership summit

February 13, 2025

Amgen to present at the 35th annual oppenheimer healthcare life sciences conference

February 6, 2025

Amgen reports fourth quarter and full year 2024 financial results

February 3, 2025

Amgen announces webcast of 2024 fourth quarter and full year financial results

January 30, 2025

FDA approves LUMAKRAS® (sotorasib) in combination with Vectibix® (panitumumab) for chemorefractory KRAS G12C-mutated metastatic colorectal cancer

January 16, 2025

Amgen to present at 43rd annual j.p. morgan healthcare conference

January 7, 2025

← Newer news releases

Calls in 2025

Decks in 2025